Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Kite's CAR-T Approved in China for Lymphoma

publication date: Jun 23, 2021

Fosun Kite Biotech, a Shanghai JV set up to develop Kite's CAR-T therapy in China, reported Yescarta (axicabtagene ciloleucel) was approved to treat relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR-T therapy allowed to launch in China. The approval was for third-line treatment. Axicabtagene ciloleucel is an autologous CD19-directed CAR T-cell therapy manufactured in China under a license from Kite. To acquire 50% of the JV, Fosun Pharma agreed to a $95 million package that will entitle it to receive 60% of the profits. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here